盐酸阿朴吗啡治疗勃起功能障碍的临床经验:最早的107例患者

作者评价了勃起功能障碍患者使用盐酸阿朴吗啡的有效性和安全性。 2 0 0 1年 7月至 11月 ,作者随机抽取因勃起功能障碍就诊的 10 7例患者 ,于性交开始前 2 0min舌下含服盐酸阿朴吗啡 ,5 1例患者的起始剂量为 2mg,5 6例患者的起始剂量为 3mg。结果显示 ,起始剂量 2mg患者的有效率为 2 3.5 % ,3mg患者为2 8.5 % ,药物总体有效率 2 6 .1%。以获得足以进行满意性交的硬度作为阳性反应 ,将剂量从 2mg提高到 3mg的患者中18.5 %达到阳性反应。根据勃起功能障碍的临床表现 ,勃起早期消退的病例疗效最好 ,完全不能勃起的病例疗效最差。总不良反应发生…     

复方玄驹胶囊治疗勃起功能障碍的疗效观察

祖国医学认为，蚂蚁是一种温和的滋补药，具有扶正固本、补肾壮阳、养血荣筋、祛淤通络等功效，其中以补肾之功效最为显著，为此，我们使用其复方制剂复方玄驹胶囊治疗了一组勃起功能障碍（ED）患者，现将治疗情况报告如下。     

复方玄驹胶囊治疗伴勃起功能障碍的慢性前列腺炎疗效观察

慢性前列腺炎(chronic postatitis,CP)是泌尿男科常见病、多发病.占男科疾病的56%以上[1],而其中青壮年占70%以上[2],且呈逐年上升趋势.其病因复杂[3],可分为急性细菌性前列腺炎、慢性细菌性前列腺炎、非细菌性前列腺炎和前列腺痛4种,其症状表现复杂,除了疼痛及排尿症状之外,无确定病因的性功能障碍尤其是勃起功能障碍(erectile dysfunction,ED)是CP患者常抱怨的问题,具有病情顽固、容易复发、疗效欠佳等特点,严重危害患者身心健康,甚至影响日常工作.     

复方玄驹胶囊联合山海丹颗粒治疗勃起功能障碍临床疗效观察

目的观察复方玄驹胶囊联合山海丹颗粒治疗勃起功能障碍。方法选择广西中医药大学第一附属医院仁爱分院男科门诊确诊为勃起功能障碍伴高脂血症患者30例,采用复方玄驹胶囊(口服,3粒/次,3次/天)和山海丹颗粒(1袋/次,3次/天),4周为一个疗程,服用三个疗程,采用自身前后对照的方法,根据服药前后各项指标的变化情况评价疗效。结果用药三个疗程后,患者IIEF-5评分显著性升高,患者总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白(LDL-C)表达水平均降低,高密度脂蛋白(HDL-C)升高。结论复方玄驹胶囊联合山海丹颗粒可以改善高血脂症患者的勃起功能,同时降低血脂,效果显著,值得临床推广使用。     

复方玄驹胶囊对勃起功能障碍患者夜间阴茎勃起的影响

目的探讨复方玄驹胶囊对勃起功能障碍(ED)患者夜间阴茎勃起的作用。方法通过RigiScan阴茎硬度检测仪对门诊就诊的32例ED患者进行夜间阴茎勃起硬度和膨胀度(NPTR)检测,根据结果分为器质性ED(13例)和心理性ED(19例)两组。两组患者完成国际勃起功能指数-5(IIEF-5)评估后给予复方玄驹胶囊口服,一日3次,一次3g,用药4周后使用RigiScan再次复测NPTR及再次完成IIEF-5评估。比较用药前后NPTR参数变化,包括勃起次数、阴茎头部有效勃起的持续时间、阴茎周径变化、阴茎头/根部硬度活动单位(RAU)及膨胀活动单位(TAU)以及IIEF-5评分变化情况。结果服用复方玄驹胶囊4周后,器质性ED组患者夜间勃起次数、阴茎头部有效勃起的持续时间、阴茎周径变化,以及阴茎头/根部RAU及TAU均有显著改善(P0.05);心理性ED组患者阴茎头部有效勃起的持续时间、平均勃起次数、阴茎周径变化有显著改善(P0.05),但头/根部的RAU及TAU与治疗前比较无统计学差异(P0.05)。器质性ED组治疗后IIEF-5评分显著改善[(7.5±2.1)vs.(5.9±1.6),P0.05],但心理性ED组治疗前后无统计学差异[(14.6±5.0)vs.(13.5±4.2),P0.05]。结论复方玄驹胶囊可改善器质性ED患者和心理性ED患者的夜间阴茎勃起状况。     

复方玄驹胶囊对慢性前列腺炎合并勃起功能障碍的疗效观察

目的:观察复方玄驹胶囊对慢性前列腺炎合并勃起功能障碍(ED)的治疗效果及安全性。方法:132例慢性前列腺炎伴发ED患者,治疗前行NIH慢性前列腺炎症状评分(NIH-CPSI)及国际勃起功能指数问卷5(IIEF-5)评分。根据治疗方式不同,将患者分为对照组(70例)及治疗组(62例)。对照组使用左氧氟沙星0.2 g,口服,2/d,连续服用4～6周,及特拉唑嗪2 mg,口服,1/晚,连续服用2个月。治疗组在上述治疗的基础上,同时使用复方玄驹胶囊2粒,口服,3/d,连续服用2个月。结果:所有患者均无严重不良反应出现,能坚持服药。治疗后2个月重新评分,对照组NIH-CPSI平均(16.5±5.9)分,较治疗前(25.1±5.5)分显著改善(P<0.05),IIEF-5平均(13.1±5.2)分,较治疗前(11.3±4.5)分有所增加,但差异无显著性(P>0.05);治疗组NIH-CPSI平均(13.4±5.7)分,IIEF-5平均(17.5±6.5)分,与治疗前比较,均改善显著(P<0.05)。对照组ED总有效率为20%,治疗组ED总有效率为74.2%,其差异有显著性(P<0.05)。结论:复方玄驹胶囊治疗慢性前列腺炎伴发ED,既可明显改善慢性前列腺炎症状,同时,对伴发的ED也有较好的疗效,无严重不良反应,值得推广使用。     

复方玄驹胶囊联合万艾可治疗万艾可渐进性失效勃起功能障碍的临床观察

目的:探讨复方玄驹胶囊联合万艾可治疗万艾可渐进性失效勃起功能障碍(ED)的临床疗效。方法:将符合万艾可渐进性失效ED诊断标准的36例患者随机分成两组,每组各18例。其中治疗组给予复方玄驹胶囊(口服,2粒/次,3次/日)和万艾可50 mg(性生活前1 h口服)口服;对照组单纯口服万艾可100 mg(性生活前1 h口服)。两组性生活频率1～2次/周,观察期2个月,对用药前后患者国际勃起功能评分(IIEF-5)及TSS伴侣评分进行对比分析。结果:两组每次使用万艾可对勃起功能改善的有效率比较,治疗组总有效率94.44%,对照组88.89%,两组对比差异无显著性意义(P>0.05)。IIEF-5评分治疗组治疗前后分别为(13.166 7±3.601 5)和(20.888 9±3.833 1),而对照组治疗前后分别为(13.055 6±2775 4)和(18.777 8±4.008 2),每组治疗前后对比差异有显著性意义(P<0.05);治疗后两组IIEF-5评分及TSS伴侣评分比较,治疗组的效果均比对照组好,且差异具有显著性意义(P<0.05)。结论:复方玄驹胶囊联合万艾可治疗万艾可渐进性失效ED疗效显著。     

复方玄驹胶囊联合溴隐亭治疗高泌乳素血症导致的勃起功能障碍的疗效观察

目的:观察复方玄驹胶囊联合溴隐亭治疗高泌乳素血症导致的勃起功能障碍的疗效。方法:46例高泌乳素血症导致勃起功能障碍患者,随机平均分为治疗组和对照组,治疗组同时口服复方玄驹胶囊(3粒,3次/d)和溴隐亭进行治疗,对照组单用溴隐亭进行治疗,治疗至病情稳定后观察勃起功能、血清泌乳素水平、血清睾酮水平变化并对疗效进行评估。结果:治疗组、对照组经治疗12周后国际勃起功能指数(IIEF-5)分别为(13.7±3.5)、(16.4±3.7),两组病例经治疗12周后勃起功能较治疗前均明显改善(P<0.05),治疗组病例勃起功能较对照组改善更显著(P<0.05),治疗组、对照组病例治疗后血清泌乳素水平分别为(156.07±26.31)mIU/L、(164.73±28.58)mIU/L,较治疗前均有显著下降(P<0.05),两组间治疗后血清泌乳素水平无显著差异(P>0.05),治疗组、对照组病例治疗后血清睾酮水平分别为(15.34±5.27)nmol/L、(12.02±2.36)nmol/L,较治疗前均有升高(P<0.05),治疗组血清睾酮水平较对照组显著升高(P<0.05),治疗组、对照组治疗后勃起功能改善有效率分别为86.96%(20/23)、65.22%(15/23),治疗组明显高于对照组(P<0.05)。结论:复方玄驹胶囊联合溴隐亭能有效治疗男性高泌乳素血症导致的勃起功能障碍,联合用药较单用溴隐亭疗效更为显著。     

复方玄驹胶囊或联合PDE5抑制剂对于男性勃起功能障碍的疗效和安全性荟萃分析

目的 利用荟萃分析探讨复方玄驹胶囊或联合PDE5抑制剂治疗男性勃起功能障碍(ED)的疗效和安全性。方法 检索PubMed数据库、Cochrane Library、Medline、中国生物医学文献数据库、CNKI数据库、VIP以及万方数据库。检索时间从建库伊始至2021年10月,纳入单用复方玄驹胶囊或联合PDE5抑制剂治疗ED的随机对照治疗(RCTs)或半随机实验(CCTs)并进行方法学的质量评估。文献数据采用RevMan 5.3软件进行统计学分析,并根据异质性进行敏感性分析以及文献的发表偏倚风险评估。结果 最终有11篇RCT文献以及1篇CCT文献纳入此次荟萃分析,共纳入病例933例。荟萃分析结果显示,与单用PDE5抑制剂比较,复方玄驹胶囊联合PDE5抑制剂的显效率[RR=1.46,95%CI(1.22,1.76),Z=4.08,P<0.01]、总有效率[RR=1.14,95%CI(1.06,1.23),Z=3.41,P<0.01]均显著提高。复方玄驹胶囊对于ED的总有效率亦优于PDE5抑制剂(P=0.04)。复方玄驹胶囊联合PDE5抑制剂的不良反应发生率与单独使用PDE5抑...     

复方玄驹胶囊治疗抗抑郁药所致性功能障碍的随机对照研究

<正>我国抑郁症发病率约为3%~5%,现有2 600万抑郁症患者[1]。目前抑郁症的治疗以抗抑郁药物治疗为主,抗抑郁治疗能改善患者的抑郁症状,但是相当部分患者治疗过程中出现性功能障碍。抗抑郁药物引起的性功能障碍是指性欲、性唤起及性高潮发生明显改变以及性交疼痛,并导致个体不适、影响人际关系[2]。1项1 022例门诊患者的多中心研究显示,所有抗抑郁药引起的性功能障碍的总发生率为59.1%,男性性功能障碍(62.4%)高于女性     

复方玄驹胶囊联合维生素E对不育患者精子染色质损伤的影响

目的:初步探讨复方玄驹胶囊联合维生素E治疗方案对轻度少精子症和/或弱精子症患者精子染色质损伤的临床疗效。方法:50例精液异常的男性不育患者随机分为实验组(n=24)和对照组(n=26),分别予以复方玄驹胶囊+维生素E和单纯维生素E治疗3个月,运用计算机辅助精液分析系统(CASA)及精子染色质结构分析(SCSA)方法分析两组患者治疗前后精液常规参数和精子DNA损伤指数(DFI),比较治疗前后精液常规参数及精子DFI的变化。结果:实验组治疗后前向运动精子率为(21.55±8.68),对照组为(21.47±11.53),两组相比差异没有统计学意义(P>0.05)。在实验组中治疗前DFI为34.09±10.32,治疗后DFI为29.57±12.19,与治疗前相比显著下降(P<0.05)。结论:复方玄驹胶囊联合维生素E治疗可有效改善不育患者精液质量,对精子染色质损伤有一定的改善作用。     

复方玄驹胶囊联合他莫西芬治疗特发性少精子症的临床研究

目的:评估复方玄驹胶囊联合他莫西芬对特发性少精子症的精液参数的影响。方法:120例特发性少精子症患者随机分为试验组(复方玄驹胶囊联合他莫西芬组)、对照组(他莫西芬组),每组各60例。每组服药3个月,观察治疗前后精子浓度及总数的变化,评估不同自然不育时间(年)对疗效的影响。结果:两组治疗后都能使精子浓度和总数提高(P<0.05),但试验组优于对照组(P<0.05)。自然不育时间≤3年者疗效优于>3年者(P<0.05)。结论:复方玄驹胶囊联合他莫西芬治疗特发性少精子症的临床疗效满意,可以作为特发性少精子症的常规治疗方法。     

来曲唑联合复方玄驹胶囊治疗肥胖性少弱精子症的临床疗效观察

目的 观察来曲唑、枸橼酸氯米芬分别联合复方玄驹胶囊及维生素E治疗肥胖性少弱精子症的临床疗效.方法 选取2018年8月至2020年8月在洛阳市妇幼保健院生殖医学研究所就诊的188例肾阳不足型肥胖性少弱精子症患者,随机分为来曲唑联合组(A组)和枸橼酸氯米芬联合组(B组)各94例,疗程为3个月,以精子浓度、精子前向运动百分率...     

An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction

Two papers in this section deal with well‐known pharmacological agents used to treat male erectile dysfunction. In the first of these, authors from the UK compared the efficacy and safety of sildenafil and apomorphine in such patients. This open‐label crossover trial suggested that sildenafil was better than apomorphine, where the primary endpoint was the erectile function domain of the International Index of Erectile Function. The second paper is an update on the efficacy and safety of tadalafil. It describes the results of its use in a large number of men with erectile dysfunction, compared to placebo. Once again, the erectile function domain was one of the primary endpoints. Tadalafil was an effective and well tolerated treatment for this condition.

OBJECTIVE

To compare the efficacy and safety of sildenafil and apomorphine in the treatment of men with erectile dysfunction (ED).

PATIENTS AND METHODS

In all, 139 men with ED who were naïve to treatment were entered into an open‐label crossover trial with two treatment periods, each of 8 weeks, separated by a 2‐week washout period. Men were randomized to receive either sildenafil then apomorphine or apomorphine then sildenafil, and were allowed to titrate the dose on both drugs. The primary endpoint was the erectile function (EF) domain of the International Index of Erectile Function (IIEF), and other endpoints included diary data, the other domains of the IIEF, overall assessment questions and the Erectile Dysfunction Index of Treatment Satisfaction (EDITS) questionnaire.

RESULTS

The EF domain score after treatment was 25.2 for sildenafil and 15.9 for apomorphine. The treatment difference of the adjusted means was 9.3 points (95% confidence interval 7.6–11.1; P < 0.001). After sildenafil the successful intercourse rate was 75%, vs 35% for apomorphine (P < 0.001), and the EDITS scores were 82.5 for sildenafil and 46.8 for apomorphine (P < 0.001). Of the men, 96% expressed a preference for sildenafil as a treatment for their ED. The side‐effect profiles for both drugs were in keeping with published data.

CONCLUSION

By all measurable endpoints sildenafil was superior to apomorphine in this open‐label crossover study of men with ED who were naïve to therapy

     

Comparative cross-over study of sildenafil and apomorphine for treating erectile dysfunction

OBJECTIVE

To compare the effectiveness, safety and tolerability of sildenafil and apomorphine in Brazilian patients with erectile dysfunction (ED) of various causes.

PATIENTS AND METHODS

In all, 108 patients (mean age 55 years, sd 11) and documented ED for ≥6 months were included in 12 centres in Brazil. The patients were initially followed for 2 weeks and then randomized to initial treatment with apomorphine or sildenafil, taken before sexual intercourse, no more than once a day. The initial dose (2 mg apomorphine and 50 mg sildenafil) could be adjusted (to 3 mg apomorphine, or to 25 or 100 mg for sildenafil) depending on the effectiveness and tolerability during the first 4 weeks of treatment. The patients were re‐evaluated after 8 weeks on treatment and, after a wash‐out period of 2 weeks (no treatment), received the other study drug (other than that received in the first phase), and then had the same procedures as in the first phase.

RESULTS

In all, 97 patients were evaluated for therapeutic effectiveness, the overall effectiveness being assessed using two questions; sildenafil had a significantly higher proportion of affirmative answers for both (P < 0.001). Likewise, the estimates for the mean (sd ) proportion of successful sexual intercourse, of 83.3 (4.7)% vs 40.3 (4.7)% and the total ED Inventory of Treatment Satisfaction score, of 86.7 (2.9) vs 56.9 (2.9) (P < 0.001) were higher for sildenafil. At the end of the study, 93.8% of the patients randomized to initial therapy with apomorphine declared a preference for sildenafil, and 81.3% of those initially treated with sildenafil declared a preference for that drug. The two drugs were well tolerated, and the main adverse events for apomorphine were nausea, vomiting, headache, taste perversion and dizziness; for sildenafil they were headache, flushing or vasodilatation, abdominal pain or dyspepsia and nasal congestion.

CONCLUSIONS

Sildenafil is more effective than apomorphine for treating ED, in the domains of erectile function, satisfaction with sexual intercourse and overall satisfaction, and was the drug preferred by most of the patients.     

精索静脉高位结扎术后联合复方玄驹胶囊治疗弱精子症

目的:观察腹腔镜精索静脉高位结扎术联合复方玄驹胶囊治疗精索静脉曲张弱精子症的疗效。方法:选择精索静脉曲张合并弱精子症患者75例,按住院号单双随机分成治疗组(n=39)和对照组(n=36),均行腹腔镜精索静脉曲张高位结扎术,术后治疗组联合复方玄驹胶囊口服,对照组静止观察。12周后对两组治疗前后精液量、精子密度、精子总活力、精子存活率、精子形态等精液参数进行分析,并对促卵泡激素(FSH)、促黄体素生成激素(LH)、睾酮(T)、血清抑制素B等激素改变进行比较。结果:两组治疗12周后,(1)治疗组精子参数显示:精液量增加(1.2±0.41)mL、精子密度增加(2.7±1.85)×106/mL、总活力增加(24.5±6.10)%、精子存活率提升(25.1±7.32)%、正常精子形态提升(2.0±1.29)%,改善均显著优于对照组(P0.01)。(2)治疗组相关激素水平显示:T提高(9.1±6.43) nmol/L、FSH下降(5.2±1.54)IU/L、LH下降(3.7±0.95)IU/L、血清抑制素B提高(26.1±15.03)pg/mL,改善均显著优于对照组(P0.01)。结论:精索静脉高位结扎术后联合复方玄驹胶囊治疗弱精子症,能较好提高精子质量,改善性激素水平,提高治疗有效率。